Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol Cyclo for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

18.10.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ... Seite 1

Related Keywords

Caroline Hastings ,Company Phase ,Trappsol Cyclo Program Steering Committee ,Society For Inherited Metabolic Disorders ,Cyclo Therapeutics Inc ,Nasdaq ,Global Principal Investigator For The Company ,Cyclo Therapeutics ,Trappsol Cyclo ,Niemann Pick Disease ,Inherited Metabolic ,Molecular Genetics ,Cyclo Program Steering Committee ,Global Principal Investigator ,